

February 25, 2026

Use Revised AHA Model Letter to Submit Comments on 340B Rebate Model RFI by New April 20 Deadline

HRSA has extended comment deadline and suggested a significantly expanded scope of rebate program

The Health Resources and Services Administration today [said it will extend the deadline to April 20](#) to receive comments on its request for information on whether to implement a 340B rebate model program.

HRSA also indicated that it may expand the 340B rebate model pilot program to all drugs included in the Inflation Reduction Act's Medicare Drug Price Negotiation Program through 2027. This means that cost and burden estimates should account for 25 total drugs across 13 drug companies. The following are just some of the new drugs that may be included in the rebate program: **Ozempic, Wegovy, Linzess, Otezla, Ibrance, Janumet, Trelegy Ellipra and Xtandi.**

TO ACCOUNT FOR THIS POTENTIAL EXPANDED SCOPE OF THE REBATE PROGRAM, THE AHA HAS SLIGHTLY REVISED ITS MODEL COMMENT LETTER.

PLEASE [CLICK HERE](#) TO DOWNLOAD THE REVISED LETTER.

It is critical that HRSA hear from as many 340B hospitals as possible about the costs and administrative burdens a rebate model program would impose. The revised model letter includes information that 340B hospitals should consider when responding to the questions contained in the RFI.

Comments on the RFI were originally due March 19. The AHA, joined by several other national groups representing 340B hospitals, last week urged HRSA to extend the original deadline to allow stakeholders to provide feedback to HRSA's detailed questions in the RFI.

Please follow the [instructions in the RFI](#) for submitting comments, which can be submitted [here](#).

Earlier this month, the AHA issued a [Special Bulletin](#) with more details about the RFI. The AHA will submit its own comment letter and share it with 340B hospitals.